Moreover, we found that the MHC-H group with better prognosis had higher mutation frequencies of TP53 and RB1 genes, which is consistent with the conclusion of one of our previous studies that TP53 mutation may predict the favorable prognosis of BC patients treated with ICIs (Lyu et al., 2020). Here, RB1 is linked to breast cancer.